Adjuvant Selpercatinib Improves EFS in Early-Stage RET+ NSCLC
In a notable development, FDA has placed a partial clinical hold on the Lorigerlimab trial involved in Gynecologic Cancers due to severe safety events such as treatment-related death.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Efforts are underway to refine the management of immune-checkpoint inhibitor toxicities in the treatment of melanoma, providing crucial insights into potential treatment advancements.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The FDA has granted the coveted fast track designation to SRN-101 to accelerate treatment options for patients with recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
A novel small molecule, notably KTX-1001, is displaying promising early activity in the treatment of patients with pretreated multiple myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
A recent study provides a comparative analysis of quality of life outcomes for patients suffering from Oropharyngeal Squamous Cell Carcinoma (OPSCC), treated with Protons versus Photons.
